Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05497297
Other study ID # HSK7653-106
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date August 4, 2022
Est. completion date October 26, 2022

Study information

Verified date August 2022
Source Haisco Pharmaceutical Group Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, single-dose study to evaluate the pharmacokinetics, pharmacodynamics and safety of HSK7653 in subjects with mild, moderate, severe renal impairment and subjects with kidney failure compared to the matched control subjects with normal renal function.


Description:

This is an open-label, single-dose Phase I study that evaluate the pharmacokinetics, pharmacodynamics and safety of a single dose of HSK7653 10 mg in subjects with mild, moderate, and severe renal impairment , subjects with kidney failure and the control subjects with normal renal function. This study consists of a screening period (Day -14 to Day -1), a baseline period (Day -1), a treatment period (Day 1 to Day 29), and a follow-up call on Day 32. Subjects will be enrolled in the following groups: Glomerular filtration rate (GFR, unit mL/min/1.73m^2) will be calculated based on Modification of Diet in Renal Disease (MDRD) equation at screening, Multiply it by BSA, then divide by 1.73 to convert to absolute GFR (unit, mL/min) (group A1) mild renal impairment (60 ≤ GFR< 90 mL/min); (group B1) moderate renal impairment (30 ≤ GFR<60 mL/min); (group C1) severe renal impairment (15 ≤ GFR< 30 mL/min); (group D1) kidney failure (<15 mL/min, not on hemodialysis); (group A2,B2,C2,D2) control subjects with normal renal function will be matched with subjects with renal impairment by weight, age, and sex (GFR≥90 mL/min).If subjects in group A2 can be matched with the subjects in groups A1 and B1 at the same time, the subjects in group B2 will not be enrolled, and so on. Approximately 64 subjects will be enrolled in total.


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date October 26, 2022
Est. primary completion date October 23, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 79 Years
Eligibility Inclusion Criteria: Subjects with renal impairment(RI): 1. Voluntarily sign the informed consent form, understand the trial procedures, and be willing to comply with all trial procedures and restrictions; 2. 18 years to 79 years (inclusive), male and female; 3. Male subjects weight =50 kg and female subjects weight =45 kg. Body mass index (BMI) : 18-30 kg/m2 (inclusive) (BMI= weight (kg)/height2 (m^2)); 4. Subjects with medically stable RI until study completion corresponding to the Classifications of Renal Function based on GFR: mild RI: 60=GFR<90 mL/min; moderate RI: 30=GFR<60 mL/min, severe RI:15=GFR<30 mL/min, kidney failure:GFR<15 mL/min (not on hemodialysis); 5. Physical examination, vital sign measurements, 12-lead electrocardiogram (ECG), and clinical laboratory tests (hematology, serum chemistry, coagulation and urinalysis test) results were deemed appropriate by the investigator; 6. Not in use of any drug within 2 weeks prior to screening, except for the medication necessary for RI/ other comorbidities (last more than four weeks in good compliance); 7. Subjects (including partners) are willing to voluntarily use effective contraceptives from screening to at least 6 months after the last dose administration; Subjects with normal renal function : 1. Voluntarily sign the informed consent form, understand the trial procedures, and be willing to comply with all trial procedures and restrictions; 2. 18 years to 79 years (inclusive), male and female, age and sex must be matched with subjects with RI; 3. Male subjects weight =50 kg and female subjects weight =45 kg, weight must be matched with subjects with RI. Body mass index (BMI) : 18-30 kg/m^2 (inclusive) (BMI= weight (kg)/height2 (m^2)); 4. 90=GFR<130 mL/min; 5. Physical examination, vital sign measurements, 12-lead electrocardiogram (ECG), and clinical laboratory tests (hematology, serum chemistry, coagulation and urinalysis test) results were deemed appropriate by the investigator; 6. Not in use of any drug within 2 weeks prior to screening, except for the medication necessary for comorbidities (last more than four weeks in good compliance); 7. Subjects (including partners) are willing to voluntarily use effective contraceptives from screening to at least 6 months after the last dose administration; Exclusion Criteria: 1. Subjects who have a allergic history of DPP4 inhibitors or have a history of allergy to the test drug and the related compounds; 2. Have a history of severe and uncontrolled diseases, such as cardiovascular, respiratory, liver, gastrointestinal, endocrine, hematologic, mental/nervous systems diseases within one year prior to screening; 3. History or clinical evidence of acute or chronic pancreatitis, or clinically significant abnormalities in blood lipase and/or blood amylase results at screening; 4. Have conditions that may affect drug absorption, distribution, metabolism, or excretion (e.g., disease, drugs or surgery); 5. Use of any DPP-IV enzyme inhibitor within 2 weeks prior to the screening; 6. Experienced severe hypoglycemia within 3 months before screening; 7. Acute renal failure; 8. Smoking more than 5 cigarettes per day within 3 months prior to screening or smoking during the study; 9. Average alcohol intake is more than 14 unit per week (1unit=17.7 mL alcohol , 1 unit=357mL 5% alcohol beer, or 43mL 40% alcohol spirit, or 147mL 12% alcohol wine) within the 3 months prior to screening, or taking any alcohol during study or a positive ethanol breath test at screening; 10. Drug abuse history within 5 years prior to screening, or positive urine drug screen at screening; 11. History of high consumption of grapefruit juice, methylxanthine-rich food or beverage (such as coffee, tea, cola, chocolate, energy drinks) , consumption of grapefruit juice, methylxanthine-rich food within 48 hours before the administration ; 12. Participation in another clinical trial within 3 months before screening; 13. Blood donation (or blood loss) =400 mL, or receiving blood products to improve anemia within 3 months prior to the screening; 14. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) > 2 × upper limit of normal, or bilirubin > 1.5 × upper limit of normal; 15. Have a positive result for hepatitis B surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, or anti-treponema pallidum specific antibody; 16. A pregnant/lactating woman, or has a positive pregnancy test at screening or during the trial; 17. Not suitable for this study as judged by the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
HSK7653 tablets
HSK7653, tablet, oral

Locations

Country Name City State
China Beijing Jishuitan Hospital Beijing

Sponsors (1)

Lead Sponsor Collaborator
Haisco Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cmax The pharmacokinetic parameters of HSK7653 in plasma Predose and 0.25, 0.5, 1, 2, 4, 8 , 12, 24, 72, 168, 336, 504, 672 hours after dosing
Primary AUC0-t The pharmacokinetic parameters of HSK7653 in plasma Predose and 0.25, 0.5, 1, 2, 4, 8 , 12, 24, 72, 168, 336, 504, 672 hours after dosing
Primary AUC0-inf The pharmacokinetic parameters of HSK7653 in plasma Predose and 0.25, 0.5, 1, 2, 4, 8 , 12, 24, 72, 168, 336, 504, 672 hours after dosing
Secondary Tmax The pharmacokinetic parameters of HSK7653 in plasma Predose and 0.25, 0.5, 1, 2, 4, 8 , 12, 24, 72, 168, 336, 504, 672 hours after dosing
Secondary t1/2 The pharmacokinetic parameters of HSK7653 in plasma Predose and 0.25, 0.5, 1, 2, 4, 8 , 12, 24, 72, 168, 336, 504, 672 hours after dosing
Secondary Vz/F The pharmacokinetic parameters of HSK7653 in plasma Predose and 0.25, 0.5, 1, 2, 4, 8 , 12, 24, 72, 168, 336, 504, 672 hours after dosing
Secondary CL/F The pharmacokinetic parameters of HSK7653 in plasma Predose and 0.25, 0.5, 1, 2, 4, 8 , 12, 24, 72, 168, 336, 504, 672 hours after dosing
Secondary Ae The pharmacokinetic parameters of HSK7653 in urine Predose and 168 hours after dosing
Secondary Fe The pharmacokinetic parameters of HSK7653 in urine Predose and 168 hours after dosing
Secondary CLr The pharmacokinetic parameters of HSK7653 in urine Predose and 168 hours after dosing
Secondary DPP4 inhibition AUEC The pharmacodynamic parameters of HSK7653 in plasma Predose and 1, 24, 72, 168, 336 hours after dosing
Secondary DPP4 inhibition Emax The pharmacodynamic parameters of HSK7653 in plasma Predose and 1, 24, 72, 168, 336 hours after dosing
Secondary DPP4 inhibition E336h The pharmacodynamic parameters of HSK7653 in plasma Predose and 1, 24, 72, 168, 336 hours after dosing
Secondary The number of volunteers with adverse events as a measure of safety The number of volunteers with adverse events as a measure of safety Day 1 to Day 32
See also
  Status Clinical Trial Phase
Completed NCT01937975 - The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050) Phase 1
Completed NCT03284164 - Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex Phase 1
Completed NCT05992155 - A Study of TAK-279 in Adults With or Without Kidney Problems Phase 1
Completed NCT05004311 - The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics Phase 1
Completed NCT04963738 - A Study of JNJ-73763989 in Adult Participants With Renal Impairment Phase 1
Terminated NCT02508740 - Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment Phase 1
Active, not recruiting NCT01529658 - Renal Hypothermia During Partial Nephrectomy N/A
Terminated NCT00984113 - Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment Phase 1
Completed NCT00750620 - A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment Phase 1
Completed NCT00842868 - The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases N/A
Completed NCT00499187 - Fanconi Syndrome Due to ARVs in HIV-Infected Persons Phase 4
Completed NCT01331941 - A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function Phase 1
Completed NCT05489614 - A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment Phase 1
Completed NCT03259087 - Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005) Phase 1
Completed NCT05086107 - Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment Phase 1
Recruiting NCT05349851 - Bowel Cleansing With Renal Impairment
Completed NCT03660241 - A Renal Impairment Study for PF-04965842 Phase 1
Recruiting NCT06037031 - A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function Phase 1
Completed NCT03289208 - Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment Phase 1
Completed NCT02942810 - To Investigate The Pharmacokinetics Of Intravenous WCK 5222 (FEP-ZID) In Patients With Renal Impairment Phase 1